Similar findings were described in another study in which administration of another non-selective CDK inhibitor, roscovitine, reversed disease-associated transcriptomic changes, reduced Aβ and Tau pathology, and improved behavioral performance in an AD mouse model [202]. This evidence concerns the gene MAPT and Alzheimer disease.